查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552602

核酸治疗 CDMO 市场规模、份额和趋势分析报告：按类型、服务、最终用途、应用、地区和细分市场预测，2024-2030 年

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

核酸疗法 CDMO 市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球核酸治疗CDMO市场规模将达到338.6亿美元，预测期内复合年增长率为14.10%。

推动该市场成长的主要因素包括对核酸治疗药物的需求增加、核酸技术的进步以及 FDA 对核酸治疗药物的核准增加，从而导致对具有成本效益的合约开发和受託製造服务的需求不断增长。

生技公司、製药公司和学术机构对基因治疗研发的投资和兴趣不断增加，正在推动对 CDMO 服务的需求。 CDMO 在基因治疗製造中发挥重要作用。例如，作为 Sarepta Therapeutics 的商业製造合作伙伴，Catalent 在推进基因治疗解决方案方面发挥关键作用。

mRNA 疫苗在应对 COVID-19 大流行方面的成功证明了核酸疗法的潜力，并刺激了该领域的进一步研究和投资。例如，赛诺菲在 2022 年 3 月宣布，将在未来几年内投入 10.2 亿美元（9.35 亿欧元）在法国开发传讯RNA疫苗。赛诺菲将在 2026 年之前进行这项投资，作为 2021 年 6 月宣布的 20 亿欧元全球投资倡议的一部分。这项倡议旨在进一步推进公司的 mRNA 策略。这种增资情境将促进市场成长。

此外，越来越多的 CDMO 收购和合作预计将在未来几年加速核酸治疗 CDMO 市场的成长。例如，2022 年 5 月，eureKARE 进行了价值 1.6098 亿美元（1.5 亿欧元）的合併，以创建一个细胞和基因治疗合约开发和製造组织 (CDMO)。

该公司成立了特殊目的收购公司 eureKING (SPAC)，以整合三个欧洲合约开发和受託製造厂商(CDMO)。此外，2022 年 4 月，FUJIFILM将透过收购位于加州 Atara Biotherapeutics, Inc. 的一家专门从事细胞治疗的製造工厂，扩大其作为先进疗法合约开发和受託製造厂商(CDMO) 的产品组合。此类倡议预计将促进市场成长。

核酸疗法 CDMO 市场报告亮点

  • 2023 年，基于 RNA 的治疗领域占据了最大的收益占有率。基于 RNA 的疗法（主要是 mRNA）提供了解决多种疾病的多功能性。它们可以被设计为产生多种治疗性蛋白质，从而适用于不同的治疗领域。
  • 预计未来几年基因治疗领域的市场将显着成长。这归功于基因治疗的临床成功，并有助于扩大基因治疗的适应症。
  • 2023年，製造业服务业占据市场主导地位，占总销售份额超过38.37%。促进该行业成长的主要挑战包括复杂的製造流程、规模化和生产挑战以及成本效率。
  • 生技公司在2023年占据领先的收益占有率，超过58%，因为它们大力投资于创新治疗方法的研发。
  • 2023年，北美在核酸治疗CDMO市场中占据最大收益占有率，达到40.24%。大量的投资和资金、强大的学术和研究机构以及 CDMO 的全球扩张正在推动该地区的成长。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 核酸治疗 CDMO 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 配套市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 2023 年临床试验数量分析
    • 按地区分類的临床试验总数（2023 年）
    • 临床试验总数（按阶段）（2023年）
    • 临床试验总数（依研究设计）（2023）
    • 按主要治疗领域分類的临床试验总数（2023 年）
  • 核酸治疗 CDMO 市场：分析工具
    • 波特五力分析
    • PESTEL分析
  • COVID-19 影响分析

第四章 核酸治疗 CDMO 市场：按类型估计和趋势分析

  • 细分仪表板
  • 全球核酸治疗CDMO市场波动分析
  • 2018-2030年全球核酸治疗CDMO市场规模及趋势分析（按类型）
  • 基因治疗
  • 基于RNA的治疗方法

第五章 核酸治疗药物CDMO市场：依服务估算及趋势分析

  • 细分仪表板
  • 全球核酸治疗CDMO市场波动分析
  • 2018-2030年全球核酸治疗CDMO市场规模及趋势分析（依服务）
  • 製程开发与最佳化
  • 製造服务
  • 分析和品管服务

第六章 核酸治疗 CDMO 市场：依最终用途分类的估算与趋势分析

  • 细分仪表板
  • 全球核酸治疗CDMO市场波动分析
  • 2018-2030年全球核酸治疗CDMO市场规模与趋势分析（依最终用途）
  • 製药公司
  • 政府及学术研究机构
  • 生技公司

第七章 核酸治疗 CDMO 市场：依应用估算与趋势分析

  • 细分仪表板
  • 全球核酸治疗CDMO市场波动分析
  • 2018年至2030年全球核酸治疗CDMO市场规模及趋势分析（依应用）
  • 罕见疾病
    • 2018 年至 2030 年市场估计与预测
  • 遗传疾病
    • 2018 年至 2030 年市场估计与预测
  • 感染疾病
    • 2018 年至 2030 年市场估计与预测
  • 其他的
    • 2018 年至 2030 年市场估计与预测

第8章 核酸治疗CDMO市场：区域估计与趋势分析

  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018 年至 2030 年市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018 年至 2030 年市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018 年至 2030 年市场估计与预测
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018 年至 2030 年市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018 年至 2030 年市场估计与预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 市场参与企业分类
    • 市场领导者
    • 新兴玩家
  • 按行业分類的竞争市场占有率（2023 年）
  • 竞争地图：依服务类型分类（2023）
  • 服务热图分析（公司比较分析）
  • 公司简介
    • Agilent Technologies, Inc
    • Curia Global, Inc.
    • Ajinomoto Co., Inc.
    • Danaher Corporation
    • KNC Laboratories Co., Ltd.
    • LGC Limited
    • Merck KGaA
    • WuXi AppTec
    • BIOSPRING
    • Exothera
Product Code: GVR-4-68040-125-4

Nucleic Acid Therapeutics CDMO Market Growth & Trends:

The global nucleic acid therapeutics CDMO market size is expected to reach USD 33.86 billion by 2030, registering a CAGR of 14.10% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights:

  • The RNA-based therapies segment held the largest revenue share in 2023. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas.
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies.
  • In 2023, the manufacturing services segment dominated the market, accounting for over 38.37% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency.
  • The biotechnology companies held a major revenue share of over 58% in 2023 due to substantial investments in the research and development of innovative therapies.
  • North America held the largest revenue share of 40.24% in the nucleic acid therapeutic CDMO market in 2023. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising incidence of genetic disorders across the globe
      • 3.2.1.2. Robust expansion of the genomics research sector and strong traction gained by custom oligonucleotides
      • 3.2.1.3. Increasing demand for one-stop-shop CDMOs and growing foreign direct investments in nucleic acid therapeutics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited outsourcing by big pharmaceutical and biopharmaceutical companies
      • 3.2.2.2. Stringent regulatory framework
  • 3.3. Clinical Trials Volume Analysis, 2023
    • 3.3.1. Total Number of Clinical Trials, by Region (2023)
    • 3.3.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.3.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.3.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.4. Nucleic Acid Therapeutics CDMO Market: Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PESTEL Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Nucleic Acid Therapeutics CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 4.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Gene Therapy
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. RNA-based Therapies
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Nucleic Acid Therapeutics CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 5.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development and Optimization
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Manufacturing Services
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.6. Analytical and Quality Control Services
    • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Nucleic Acid Therapeutics CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 6.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Government & Academic Research Institutes
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Biotech Companies
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Nucleic Acid Therapeutics CDMO Market: Application Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 7.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, Application, 2018 to 2030 (USD Million)
  • 7.4. Rare Diseases
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Genetic Disorders
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Infectious Diseases
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Nucleic Acid Therapeutics CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Global Regional Market Snapshot
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Scenario
      • 8.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Scenario
      • 8.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Scenario
      • 8.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Scenario
      • 8.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Scenario
      • 8.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Scenario
      • 8.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Scenario
      • 8.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Scenario
      • 8.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Scenario
      • 8.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Scenario
      • 8.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Scenario
      • 8.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Scenario
      • 8.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.3. Japan
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Scenario
      • 8.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Scenario
      • 8.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Scenario
      • 8.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Scenario
      • 8.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Scenario
      • 8.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Scenario
      • 8.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Scenario
      • 8.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Scenario
      • 8.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Scenario
      • 8.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Scenario
      • 8.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Scenario
      • 8.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Competitive Market share, by Industry (2023)
  • 9.3. Competition Mapping by Service Type (2023)
  • 9.4. Service Heat Map Analysis (a comparative analysis of the players together)
  • 9.5. Company Profiles
    • 9.5.1. Agilent Technologies, Inc
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Service Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Curia Global, Inc.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Service Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Ajinomoto Co., Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Service Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Danaher Corporation
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Service Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. KNC Laboratories Co., Ltd.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Service Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. LGC Limited
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Service Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Merck KGaA
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Service Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. WuXi AppTec
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Service Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. BIOSPRING
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Service Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Exothera
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Service Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 5 Global Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 7 Global Nucleic Acid Therapeutics CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 10 North America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 12 North America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 13 U.S Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 14 U.S Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 15 U.S Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 16 U.S Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 17 Canada Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 18 Canada Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 19 Canada Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 21 Mexico Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 23 Mexico Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Mexico Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 25 Europe Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 27 Europe Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 28 Europe Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Europe Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 30 Germany Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 32 Germany Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Germany Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 34 UK Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 35 UK Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 36 UK Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 37 UK Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 38 France Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 39 France Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 40 France Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 41 France Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 42 Italy Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 43 Italy Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 44 Italy Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Italy Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 46 Spain Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 47 Spain Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 48 Spain Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Spain Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 50 Denmark Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 52 Denmark Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 53 Denmark Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 54 Sweden Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 55 Sweden Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 56 Sweden Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Sweden Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 58 Norway Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 59 Norway Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 60 Norway Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Norway Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 67 China Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 68 China Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 69 China Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 70 China Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 71 Japan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 72 Japan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 73 Japan Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Japan Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 75 India Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 76 India Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 77 India Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 78 India Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 79 South Korea Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 80 South Korea Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 81 South Korea Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 82 South Korea Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 83 Australia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 84 Australia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 85 Australia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Australia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 87 Thailand Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 88 Thailand Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 89 Thailand Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 90 Thailand Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 91 Latin America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 93 Latin America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 94 Latin America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Latin America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 96 Brazil Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 97 Brazil Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 98 Brazil Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 99 Brazil Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 100 Argentina Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 101 Argentina Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 102 Argentina Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 103 Argentina Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 109 South Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 110 South Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 111 South Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 112 South Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 117 UAE Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 118 UAE Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 119 UAE Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 120 UAE Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Nucleic Acid Therapeutics CDMO Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Nucleic Acid Therapeutics CDMO, for Gene Therapy, 2018 - 2030 (USD Million)
  • Fig. 13 Global Nucleic Acid Therapeutics CDMO, for RNA-based Therapies, 2018 - 2030 (USD Million)
  • Fig. 14 Global Nucleic Acid Therapeutics CDMO, for Process Development and Optimization, 2018 - 2030 (USD Million)
  • Fig. 15 Global Nucleic Acid Therapeutics CDMO, for Manufacturing Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Nucleic Acid Therapeutics CDMO, for Analytical and Quality Control Services, 2018 - 2030 (USD Million)
  • Fig. 17 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 Global Nucleic Acid Therapeutics CDMO, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Nucleic Acid Therapeutics CDMO, for Government & Academic Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 20 Global Nucleic Acid Therapeutics CDMO, for Biotech Companies, 2018 - 2030 (USD Million)
  • Fig. 21 Global Nucleic Acid Therapeutics CDMO, for Rare Diseases, 2018 - 2030 (USD Million)
  • Fig. 22 Global Nucleic Acid Therapeutics CDMO, for Genetic Disorders, 2018 - 2030 (USD Million)
  • Fig. 23 Global Nucleic Acid Therapeutics CDMO, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 24 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Outlook, 2023 & 2030
  • Fig. 26 North America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Germany Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 France Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Italy Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Spain Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Denmark Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Asia Pacific Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Japan Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 China Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 India Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Australia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Latin America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Brazil Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)